Summary

The goal of this prospective study is to determine the effects of a modified fluid gelatin solution (MFG) (a synthetic colloid) in normal horses.
Specifically, eight normal adult horses will receive 3 different doses (low, medium and high) of the colloid and a control solution via intravenous infusion, with a washout period in between treatments. The effects of each dose on plasma oncotic pressure, haemostasis, haemodilution and clinical evaluation will be determined from sequential blood samples obtained during and after the infusion over a 24 hour period.
Results of laboratory tests will be used to determine the efficacy of the colloid in terms of magnitude and duration of increase in colloid oncotic pressure. Possible negative effects of the colloid on hemostatis and anaphylactic reactions will be determined by measurement of coagulation parameters, and frequent clinical observation and monitoring.
Using this data, guidelines for the safe and efficacious administration of the colloid solution in horses can be established. From this baseline information determined in normal horses can come further studies into its efficacy in clinically ill horses.

Program

Thoroughbred Horses

Research Organisation

The University of Sydney

Objective Summary

The main objective of this study is to investigate the oncotic, haemodilutional, and haemostatic effects of 3 different infusion doses of the MFG (Gelofusine®) compared with infusion of a control solution (balanced crystalloid fluid) in normal horses.
The specific aims of the study are;
1. To determine an infusion dose of MFG that effectively increases colloid oncotic pressure, and the duration of effect.
2. To assess degree of plasma volume expansion induced by each dose of MFG indirectly by measuring indices of haemodilution.
3. To determine the effects of each dose of MFG on primary and secondary haemostasis by measuring various blood coagulation parameters.
4. To observe for any adverse reactions of MFG.

The ultimate goal of the study is to determine a safe and effective dose range, and frequency of administration of MFG for use in normal horses, and to provide baseline data to direct therapy and further investigation in clinical equine patients.